UK-based Endeavour Specialty Chemicals has launched a range of thioamide intermediates, citing growing evidence of their potential role in development of new cancer treatments.
Global API service provider, ScinoPharm, is to begin the commercial manufacture of vilazodone hydrochloride, the active pharmaceutical ingredient (API) in Clinical Data Inc.'s new antidepressant, Viibryd.
SurModics is still considering “strategic alternatives” for its pharmaceutical business, which has seen revenues continue to decline in the first quarter of 2011.
Hospira has confirmed it will no longer make Pentothal - an anaesthetic used in lethal injections – as the company “never condoned” its use in executions.
The US FDA has suggested pharmaceutical firms use a maximum bead size of 2.0mm for modified-release drugs formulated for “sprinkle” delivery to avoid problems resulting from inadvertent chewing.
A magnetically controlled pill may boost the body’s absorption of drugs by safely securing the tablet at the right site in the gastrointestinal (GI) tract, say researchers at Brown University, US.
ShangPharma has opened a multi-purpose pharmaceutical development cGMP manufacturing facility in Fengxian, China, and started operations on the initial phase of production.
Rentschler Biotechnologie has inked a deal to become the sole manufacturer of recombinant human interferon beta-1a (IFN-beta 1a) API for Faron Pharmaceutical.
Enlight Biosciences, a Boston, US-based drug discovery and development technologies company, has formed the new company, Entrega, which focuses on oral drug delivery techniques.
The European Medicines Agency (EMA) has highlighted the quality APIs manufactured outside the EU as an area of concern in the draft 2015 road map it unveiled this week.
Novartis will build a new $500m (€379.9m) pharmaceutical manufacturing plant in St Petersburg, Russia after signing a Memorandum of Understanding (MoU) with the city.
Big pharma continued to cut in 2010, closing plants and laying off staff in an attempt to cut costs and adjust post-merger. in-PharmaTechnologist presents a round up of five of the most read in 2010.
Bayer HealthCare is investing €35m ($47m) in a new centre for the biotechnological production of ‘innovative’ pharmaceuticals to be used in clinical trials.
Intercell has killed development of its Travellers’ Diarrhoea Vaccine Patch after the product failed in clinical trials which will lead to job cuts and a dramatic reduction of R&D expenses.
Pharma should forget about ‘the next blockbuster drug’ and invest more money creating novel drug delivery systems with emerging developers to enhance product value and efficacy, say researchers.
Vical has published a review of Vaxfectin data showing the adjuvant boosts the immune response of DNA-based vaccines against cancer and a range of pathogens.
DSM Special Products and DSM IP Assets look set to be sold to equity investor Sun Capital as the European Commission has given competition approval with no strings attached.